Abbott Laboratories (NYSE:ABT) reported Q2 adjusted earnings Thursday of $1.08 per diluted share, down from $1.43 a year earlier.
Analysts polled by Capital IQ expected adjusted EPS of $1.05.
Net sales for the quarter ended June 30 were $9.98 billion, down from $11.26 billion a year earlier. Analysts surveyed by Capital IQ expected $9.72 billion.
For the full-year 2023, the company reaffirmed its adjusted EPS guidance of $4.30 to $4.50. Analysts surveyed by Capital IQ expect $4.40.